Biliary Atresia is a neonatal liver disease, which is characterized by progressive obstruction and fibrosis of the extrahepatic biliary tree and fibrosis and inflammation of the liver parenchyma.
There are two types of Biliary Atresia, a fetal form that develops during fetal life and a more common perinatal form, which does not become evident until the second to fourth week of the infant's life. Some children, particularly those with the fetal form of Biliary Atresia, have other congenital disabilities in the heart, spleen, or intestines.
The causes of biliary Atresia are not entirely understood. For some children, Biliary Atresia may occur because the bile ducts did not form properly during pregnancy. For other children with Biliary Atresia, the bile ducts may be damaged by the body's immune system due to a viral infection acquired after birth.
Biliary Atresia Epidemiological Segmentation
The Epidemiological Segmentation of Biliary Atresia in 7MM from 2017 to 2030 is segmented as:-
- Total Incident Cases of Biliary Atresia
- Gender-Specific Cases of Biliary Atresia
- Type-Specific Cases of Biliary Atresia
- Diagnosed and Treatable Cases of Biliary Atresia
Biliary Atresia Epidemiology
- The total incident cases of Biliary Atresia in 7MM were 613 in 2017
- The incident cases of Biliary Atresia in the United Kingdom were 45 in 2017
- The incident cases of Biliary Atresia in France were 42 in 2017
- The incident cases of Biliary Atresia in Spain were 27 in 2017
The market size of Biliary Atresia in 7MM was USD 2.9 million in 2017
Biliary Atresia Emerging Drugs
The emerging drugs of the Biliary Atresia market are Odevixibat, Obeticholic Acid, and many others.
Biliary Atresia Key Players
The key players in the Biliary Atresia market are Albireo, Intercept Pharmaceuticals, and many others.